Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous alpha lipoic acid for severe COVID-19
ChiCTR2000029851Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of alpha-lipoic acid in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Sequential Organ Failure Assessment score. Started Feb 2020; status: recruiting.
02
Drugs
alpha-lipoic acid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029851.